Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaXTAE:KMDA -0.28%84 Shareholder Yield % is 3.21% as of Mar. 2026. GuruFocus rates XTAE:KMDA with a GF Score™ of 84/100 and a GF Value™ of ₪25.14 (Modestly Undervalued). Among 974 Drug Manufacturers companies, Kamada ranks better than 72.07% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Kamada's Shareholder Yield % was 3.21%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Kamada Shareholder Yield % Related Terms
Kamada Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Kamada's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:KMDA vs ZTS, UTHR, VTRS: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Kamada's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Kamada (XTAE:KMDA) has a Shareholder Yield % of 3.21% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kamada and its competitors. According to the industry distribution chart, Kamada ranks #272 out of 974 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Kamada's Shareholder Yield % too high?
Kamada's current Shareholder Yield % is 3.21%. The Drug Manufacturers industry median Shareholder Yield % is 0.32. Kamada's value of 3.21% is 919% above this industry median. Based on the distribution chart, Kamada ranks #272 out of 974 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kamada has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #272 out of 974 companies for Shareholder Yield %. This puts Kamada in the upper half of its industry. The industry median Shareholder Yield % is 0.32. Kamada's value of 3.21% is 919% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.32, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current Shareholder Yield % of 3.21% is 919% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current Shareholder Yield % is 3.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪25.14, compared to a current price of ₪21.74 — trading 13.5% below its estimated fair value. The current Shareholder Yield % is 3.21% and 919% above the Drug Manufacturers industry median of 0.32. Kamada's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current Shareholder Yield % is 3.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (XTAE:KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of ₪21.74 is trading 13.5% below its estimated GF Value™ of ₪25.14.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for XTAE:KMDA:
Shareholder Yield %: 3.21%
GF Value™: ₪25.14 vs. price of ₪21.74 (13.5% below fair value)
Industry Position: 919% above the Drug Manufacturers median (#272 of 974)
No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score
Get the complete analysis for XTAE:KMDA
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KMDA has been successfully added to your 
